Lixisenatide also increased chylomicron triacylglycerol clearance [58], whereas dulaglutide did not reduce postprandial apoB48 concentrations after a meal in a small study in Japanese people with type 2 diabetes [59]. This evidence concerns the gene APOB and type 2 diabetes mellitus.